The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain

Table 4

Laboratory parameters at week 6 and week 12.

	⁢5-ALA-SFC			⁢Placebo
		Mean	Change from baseline; Mean (SE)		Mean	Change from baseline; Mean (SE)
Total cholesterol (mg/dL)
Week 6	27	166.9	−5.2 (3.7)	13	150.3	−7.6 (5.5)
Week 12	25	181.4	6.8 (3.5)	13	160.2	−0.1 (5.0)
LDL cholesterol (mg/dL)
Week 6	27	109.4	−2.9 (3.2)	13	92.4	−11.8 (4.7)
Week 12	25	121.4	7.6 (3.3)	13	101.2	−4.0 (4.6)
HDL cholesterol (mg/dL)
Week 6	27	40.2	−0.8 (1.0)	13	37.0	−1.6 (1.4)
Week 12	25	41.9	0.5 (1.0)	13	37.4	−1.1 (1.4)
Triglycerides (mg/dL)
Week 6	27	156.6	−1.3 (14.6)	13	150.4	4.5 (21.1)
Week 12	25	163.9	3.2 (11.1)	13	159.0	11.9 (15.4)
BUN (mg/dL)
Week 6	25	14.05	1.19 (0.573)	11	13.42	−0.43 (0.665)
Week 12	26	13.87	1.28 (0.606)	12	13.00	−0.54 (0.816)
Serum creatinine (mg/dL)
Week 6	28	0.96	0.01 (0.021)	13	1.04	−0.01 (0.023)
Week 12	26	0.96	−0.00 (0.016)	13	1.06	0.01 (0.026)
Ferritin (mg/dL)
Week 6	26	169.03	31.12 (9.480)	12	136.48	−12.59 (9.033)
Week 12	22	148.71	16.64 (11.289)	12	137.54	−11.53 (14.456)
Serum iron (mg/dL)
Week 6	27	18.16	0.87 (1.330)	12	16.14	−2.27 (1.502)
Week 12	22	17.73	1.41 (1.409)	12	16.74	−1.67 (1.083)
Transferrin saturation (%)
Week 6	25	31.38	3.77 (2.960)	12	28.48	−3.43 (2.562)
Week 12	21	29.93	3.37 (2.638)	12	29.55	−2.36 (1.753)

Compared to baseline mean for only the subjects with a result for the visit.